Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...

Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

A college football player in the Inland Empire isn’t letting his cancer diagnosis stop him from pursuing his passion. Torryn ...

Social Vulnerability Index scores inversely correlated with dietary fiber intake, suggesting social determinants may shape diet patterns relevant to microbiome-associated immunotherapy response. Whole ...

A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS versus placebo in high-grade uterine sarcomas. Median PFS was identical at 3.7 ...

Maariya Khan was left with minimal movement after needing surgery following her cancer diagnosis.

A United States-based Nigerian cancer scientist, Rahmon Kanmodi, has called for increased investment in musculoskeletal cancer research across Africa, with particular focus on Nigeria.Kanmodi, a ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On ...

Iovance Biotherapeutics reported early clinical trial data for lifileucel in advanced soft tissue sarcomas, showing promising efficacy signals. The company also received FDA Fast Track designation for ...

Among the key speakers was Associate Professor Johnny Ong, Head and Senior Consultant of the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT) at the National Cancer Cen ...